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Crystal structureThe antineoplastic target aldo–keto reductase family member 1B10 (AKR1B10) and the critical
polyol pathway enzyme aldose reductase (AKR1B1) share high structural similarity. Crystal
structures reported here reveal a surprising Trp112 native conformation stabilized by a speciﬁc
Gln114-centered hydrogen bond network in the AKR1B10 holoenzyme, and suggest that AKR1B1
inhibitors could retain their binding afﬁnities toward AKR1B10 by inducing Trp112 ﬂip to result
in an ‘‘AKR1B1-like’’ active site in AKR1B10, while selective AKR1B10 inhibitors can take advantage
of the broader active site of AKR1B10 provided by the native Trp112 side-chain orientation.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The NADPH dependent aldo–keto reductase (AKR) superfamily
consists of around 150 critical phase I metabolizing enzymes that
share high sequence similarities [1,2]. The failure of decades-long
efforts to develop inhibitors of AKR1B1 (aldose reductase), which
has been a leading drug target for type 2 diabetic complications
since the 1990s, is partially related to adverse effects caused by
cross-inhibition with other AKRs, such as AKR1A1 (aldehyde reduc-
tase, 65% sequence identity) [3,4]. AKR1B10, also called small intes-
tine aldose reductase [5], is abnormally over-expressed in many
malignant tumors [6], and could be responsible for carcinogenesis
and chemoresistance by interrupting cell differentiation induced
by retinoid acids [7], impairing cell apoptosis mediated by intracel-
lular toxic carbonyls and isoprenyl aldehydes [8], and metabolizing
anti-cancer drugs such as daunorubicin and idarubicin [9]. As a
promising antineoplastic target, efforts have been expended on
developing potent and speciﬁc AKR1B10 inhibitors [10–13].
Considering the 71% sequence identity and shared substrate
speciﬁcity of AKR1B10 and AKR1B1, a clear understanding ofinhibitor–enzyme interactions is essential for designing and
screening speciﬁc AKR1B10/AKR1B1 inhibitors. Although over
100 crystal structures of AKR1B1 and its complexes with inhibitors
have been determined, only one structure of AKR1B10 (in complex
with a powerful AKR1B1 inhibitor tolrestat, PDB ID: 1ZUA) is avail-
able [7]. During the preparation of this manuscript, however, two
more structures, e.g., AKR1B10 V301L mutant in complex with
AKR1B1 inhibitors ﬁdalrestat and sorbinil were reported (PDB ID:
4GAB and 4GA8, respectively) [14]. These AKR1B10 structures
show almost identical inhibitor binding patterns to that of the cor-
responding AKR1B1–inhibitor complex structures (with tolrestat,
ﬁdarestat and sorbinil, PDB ID: 2FZD, 1EF3, 2PDK, respectively).
However, this observed inhibitor binding pattern similarity cannot
explain the speciﬁcity of selective AKR1B10 inhibitors, such as ole-
anolic acid [10] (Table 1 and Table S1 of the Supplementary data).
Here, we report the crystal structures of AKR1B10 holoenzyme
(AKR1B10-NADP+), its complexes with two AKR1B1 inhibitors
(zopolrestat and epalrestat), one selective AKR1B10 inhibitor
(ﬂufenamic acid), and the AKR1B1-NADP+–epalrestat complex
(PDB ID: 4GQG, 4JII, 4JIH, 4I5X and 4JIR, see Table S2 for data
collection and reﬁnement statistics). These structures reveal a
surprising Trp112 native conformation stabilized by a speciﬁc
Gln114-centered hydrogen bond network in the AKR1B10 holoen-
zyme, and suggest that by inducing Trp112 ﬂip to result in an
‘‘AKR1B1-like’’ active site in AKR1B10, some AKR1B1 inhibitors
retain their binding afﬁnities toward AKR1B10. Furthermore, these
Table 1
Characteristics of inhibitors and crystal structures discussed in this work.
Enzymes inhibitors IC50 (lM) Trp112 conformation Speciﬁcity pocket
B10 B1 B10 WT B10 mut B10 B10 B1
Tolrestat* 0.054 0.0014 n.d. n.d. B1-position (1ZUA) Open Open (2FZD)
Sorbinil* 9.6 0.55 n.d. n.d. B1-position (4GAB) Open Closed (2PDK)
Fidarestat* 33 0.026 n.d. n.d. B1-position (4GA8) Open Closed (1EF3)
Holoenzyme B10-position (4GQG) Closed Closed* (1UZO)
Zopolrestat 0.62* 0.018* 0.17 0.36 B1-position (4JII) Open Open* (2FZ8)
Epalrestat 0.33* 0.021* 0.35 0.52 B10-position (4JIH) Closed Closed (4JIR)
Flufenamic acid 0.76* 41* 2.14 25 B10-position (4I5X) Closed Closed#
Oleanolic acid 0.09* 124* 0.8 14 B10-position# Closed# Closed#
(B10 WT, wide type AKR1B10; B10 mut, AKR1B10 Q114T/S304C double mutant.
n.d: not determined.
* Data from references.
# Predicated.
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advantage of the broader active site of AKR1B10 provided by the
native Trp112 side-chain orientation. The Trp112 (Trp111) side
chain orientation of AKR1B10 (AKR1B1) thus could play a critical
role in the determination of inhibitor selectivity between these
two enzymes. These results provide an important structural basis
for future drug development targeting AKR1B10 (AKR1B1).
2. Materials and methods
2.1. Materials and enzyme preparation
The enzyme was prepared using the method reported by
Gallego [7]. Zopolrestat, ﬂufenamic acid, epalrestat, and other re-
agents were purchased from Sigma–Aldrich.
2.2. Crystallization, data collection and structure determination
The AKR1B10-NADP+ holoenzyme crystal was obtained at 289 K
in hanging droplets consisting of protein solution mixed with a res-
ervoir solution comprising 30–35% (w/v) PEG 6000 and 100 mM
Tris-base (pH 9.0) at a 4:3 ratio. AKR1B10-NADP+–inhibitor ternary
complex crystals were prepared by co-crystallization. The crystal
of the AKR1B1-NADP+–epalrestat ternary complex was prepared
as described previously [15]. X-ray diffraction data were collected
at 100 K on an in-house Oxford Diffraction Xcalibur Nova diffrac-
tometer. The structures were determined with CCP4 [16], Phenix
[17] and COOT [18], while molecular docking was performed by
Discovery Studio 2.5. All crystal structural ﬁgures were produced
using PyMOL. Data collection and reﬁnement statistics are summa-
rized in Table S2.3. Results and discussion
3.1. The structure of the AKR1B10 holoenzyme reveals a surprising
Trp112 native conformation stabilized by a speciﬁc Gln114-centered
hydrogen bond network
Structure superposition of our AKR1B10 holoenzyme and the
previously reported AKR1B10–tolrestat complex structure reveals
two signiﬁcant differences in the conformations (overall r.m.s.
deviation for 314 Ca atoms is 0.49 Å): (1) a different side-chain
orientation of Trp112, and (2) a shift of Val301-Leu302-Gln303-
Ser304 segment (Fig. 1B).
In the active site of the AKR1B10–tolrestat complex, Trp112 is
located between the anionic site, formed by Tyr49, His111 and
the nicotinamide moiety of NADP+, and the so-called ‘‘speciﬁcity
pocket’’ located at the interface of a loop consisting of Lys-125 to
Ala-131 and the C-terminal loop (Fig. 1A). The Try112 side chain
points to the anionic site. This orientation is the same as that of
Trp111, the residue corresponding to Trp112 in all AKR1B1 struc-
tures. Although all other residues in the active site of the AKR1B10
holoenzyme structure generally overlap well with these in the
AKR1B10–tolrestat complex structure, the side chain of Trp112
points to the ‘‘speciﬁcity pocket’’ instead. This Trp112 side chain
orientation is therefore termed the ‘‘B10-position,’’ while that of
Trp112 in AKR1B10–tolrestat complex structure and Trp111 in
AKR1B1 is termed the ‘‘B1-position’’.
Trp112 (Trp111) is a highly conserved residue in all known 14
AKR1B enzymes (Fig. S3). A careful check of the published
structures for six AKR1B enzymes reveals that the corresponding
residue Trp112 of AKR1B14 holoenzyme (rat aldose-reductase-like
protein, PDB ID: 3O3R and 3QKZ) adopts the ‘‘B10-position’’
(Fig. S4) [19], while Trp111 of AKR1B4 (Schistosoma japonicum
Fig. 1. Inhibitor-induced ‘‘speciﬁcity pocket’’ opening and change in the Trp112 side-chain conformation in AKR1B10. (A) Cartoon view of superimposed holoenzyme
structures of AKR1B10 (green) and AKR1B1 (violet). Trp112 at the B10-position (green sticks) points to the speciﬁcity pocket, while Trp112 (Trp111) at the B1-position orients
to the anionic pocket. (B–D): Superposition of the holo-AKR1B10 (green) active site structure with those of AKR1B10-tolrestat (grey and light pink), AKR1B10-zopolrestat
(grey and yellow) and AKR1B10-epalrestat (grey and cyan), respectively. The FoFc density maps are contoured in light blue at 2r. Hydrogen bonds are shown as dashed red
lines.
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with zopolrestat (ﬁbroblast growth factor induced protein, PDB
ID: 1FRB) adopt the ‘‘B1-position’’ [20,21]. In the holo-AKR1B9
structure (Chinese hamster ovary reductase, PDB ID: 1C9W), the
corresponding residue (Trp111) is located at a transitional position
between the ‘‘B1-position’’ and the ‘‘B10-position’’, Fig. S4) [22].
The conformation of ‘‘B10-position’’ Trp112 in the AKR1B10
holoenzyme is very likely to be stabilized by a speciﬁc hydrogen
bond network centered on Gln114 (Gln114 e1O  Trp112 e1N
2.80 Å, Gln114 e1O  Ser304 OG 2.65 Å and Gln114 e2N  Ser304
OG 2.73 Å, Fig. 1B). A similar hydrogen bond network (Trp112,
Gln114 and Thr304) was observed in the AKR1B14 structure, while
in AKR1B1/AKR1B4 structures, the corresponding residues
(Trp111, Thr113 and Cys303 of AKR1B1, Trp111, Val113 and
Met298 of AKR1B4) are not able to form a similar hydrogen bond
network. For AKR1B9, the steric interaction of the Met306 side
chain apparently restricts Gln113 (corresponding to Gln114 ofAKR1B10) from forming a hydrogen bond network with Trp111
and Thr303. The ‘‘B1-position’’ of Trp111 in the AKR1B8–zopolre-
stat complex apparently results from binding of the inhibitor, as
discussed below.
3.2. AKR1B1 inhibitor induced ﬂip of Trp112 and formation of
‘‘AKR1B1-like’’ active site in AKR1B10 explains their activities toward
AKR1B10
The coexistence of the shift of the Val301-Leu302-Gln303-
Ser304 segment and the ﬂip of Trp112 in AKR1B10–inhibitor struc-
tures is by no means coincidental. The shift of that segment is actu-
ally a result of opening of the ‘‘speciﬁcity pocket’’, a critical
inhibitor induced sub-pocket in AKR1B1/inhibitor complex
structures.
The AKR1B1 ‘‘speciﬁcity pocket’’ is primarily comprised of
Thr113, Phe-115, Phe-122, Leu-300, Ser302 and Cys303, and is in
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AKR1B1 inhibitors, such as tolrestat [23] and zopolrestat [24], this
‘‘speciﬁcity pocket’’ changes to an open state to bind the hydropho-
bic portion of the inhibitors. This ‘‘speciﬁcity pocket’’ was believed
to be essential for inhibitor selectivity between AKR1B1 and
AKR1A1, since there is no such a pocket formed in AKR1A1 [23].
In the AKR1B10–tolrestat structure, a similar ‘‘speciﬁcity pocket’’
composed of Gln114, Phe116, Phe123, Val301, Gln303, and
Ser304 was also observed, although at that time it was uncertain
if this ‘‘speciﬁcity pocket’’ is really in the closed state in the holo-
enzyme [7].
The AKR1B10 holoenzyme structure shows that binding of tol-
restat indeed induces the ‘‘speciﬁcity pocket’’ transformation from
a closed to an open state. The shift of the Val301-Leu302-Gln303-
Ser304 segment moves Ser304 and Leu302 away from their native
positions, and results in collapse of the Gln114-centered hydrogen
bond network. The loss of this stabilizing force causes a Trp112
side-chain ﬂip, e.g., a switch of ‘‘B10-position’’ to ‘‘B1-position,’’
and forms an ‘‘AKR1B1-like’’ active site in AKR1B10. A strong
hydrogen bond (Ne1@Trp112 and Oe2@tolrestat, 2.81 Å) thus
forms between the carboxylate group of tolrestat and Ne1 of
Trp112 side chain, as is observed in the AKR1B1–tolrestat complex
structure.
Other structures determined in this work support this inhibitor
induced ‘‘AKR1B1-like’’ active site mechanism. Zopolrestat also
opens the ‘‘speciﬁcity pocket’’ in AKR1B10, and induces formation
of an ‘‘AKR1B1-like’’ active site in AKR1B10 (Fig. 1C). In contrast,
the AKR1B1 inhibitor epalrestat, which does not result in an
opening of the ‘‘speciﬁcity pocket’’ in AKR1B1, neither opens the
‘‘speciﬁcity pocket’’ nor induces an ‘‘AKR1B1-like’’ active site in
AKR1B10. The same is true for the selective AKR1B10 inhibitor
ﬂufenamic acid (Figs. 1D, E and 2A).
The inhibitor induced ‘‘AKR1B1-like’’ active site mechanism
explains the activities of the AKR1B1 inhibitors toward AKR1B10.
For tolrestat and zopolrestat (and very likely all other AKR1B1
inhibitors with high AKR1A1 selectivity), the induced ‘‘AKR1B1-
like’’ active site in AKR1B10 is consistent with strong inhibition
of AKR1B10, while extra energy is required to induce an
‘‘AKR1B1-like’’ active site, making them weaker inhibitors toward
AKR1B10 than AKR1B1. For cyclic imide based AKR1B1 inhibitors,
minalrestat induces opening of the ‘‘speciﬁcity pocket’’ of AKR1B1
and strongly inhibits AKR1B10, while sorbinil cannot cause a ﬂip of
Trp112. Thus, the missing critical hydrogen bond between sorbinil
and Trp111 in AKR1B1 explains the weak inhibition of sorbinil
toward AKR1B10 [23,25–27]. On the other hand, the AKR1B1
inhibitor epalrestat also cannot induce an ‘‘AKR1B1-like’’ active
site in AKR1B10, but unlike sorbinil, epalrestat can rotate its thia-
zolidinone plane by ca. 60 to ﬁt in the active site of AKR1B10Fig. 2. Binding sites of (A) AKR1B10–ﬂufenamic acid crystal structure and (B) AKR1B1
AKR1B10: grey, Trp112 at B1-position: violet, hydrogen bond: red dashed line, unfavorab
sphere. The FoFc map is contoured in dark blue at 2r for ﬂufenamic acid.(Fig. 1D and E). Therefore, epalrestat still strongly inhibits
AKR1B10. The 1300-fold decreased activity of ﬁdarestat towards
AKR1B10 could be partially explained by a signiﬁcant steric inter-
action (1.2 Å) between the Val301 side chain of AKR1B10 and the
exocyclic amide of ﬁdarestat, as revealed by overlap of the
AKR1B1–ﬁdarestat complex and the AKR1B10 holoenzyme struc-
tures. This explanation is supported by the 20-fold activity incre-
ment with the AKR1B10 V301L mutation [14]. Furthermore, the
observation of Ruiz et al. that AKR1B10–ﬁdarestat and AKR1B10–
sorbinil complex structures could only be obtained via inhibitor
replacement of AKR1B10 V301L-tolrestat crystals clearly indicates
the importance of a preformed ‘‘AKR1B1 like’’ AKR1B10 induced by
tolrestat [14].
3.3. A broader entrance to the anionic site in AKR1B10 due to the
native Trp112 conformation explains the selectivity of rigid and bulky
AKR1B10 inhibitors
The crystal structure of AKR1B10 in complex with ﬂufenamic
acid provides a straightforward structural basis for the generally
rigid and bulky structures of selective AKR1B10 inhibitors. The
native conformation of Trp112 (B10-position) results in a more
accessible entrance to the anionic site in AKR1B10 than in AKR1B1,
thus allowing the carboxylic group of ﬂufenamic acid to occupy the
anionic site and form critical hydrogen bonds with His111 e2 N
(2.86 Å), Tyr49 OH (2.57 Å) and Lys78 via a bridging water and
close contact (3.28 Å) with the C4 atom of the coenzyme
(Fig. 2A). Such interactions are unlikely to occur upon binding of
ﬂufenamic acid with AKR1B1 because of unfavorable steric interac-
tions (ca. 2.4 Å) between the indole ring of Trp111 and the benzoic
acid ring of ﬂufenamic acid. As a result, ﬂufenamic acid is a much
weaker inhibitor toward AKR1B1 (IC50: 41 lM vs. 0.76 lM, see
Table 1).
In light of the increased accessibility of the anionic site in
AKR1B10, we reexamined previously published molecular docking
studies of the AKR1B10/oleanolic acid complex, which suggested
that the 3b-hydroxyl group of oleanolic acid forms hydrogen bonds
with anionic site residues (oleanolic acid O  His111 e2N, 3.4 Å;
oleanolic acid O  Tyr49 OH, 3.6 Å) [10]. Based on our crystal struc-
ture of AKR1B10–ﬂufenamic acid, we found that the carboxylic
group of oleanolic acid can be docked into the anionic site with
two hydrogen bonds (oleanolic acid O2  Tyr49 OH, 2.8 Å; olean-
olic acid O3  His111 e2 N, 2.9 Å), and a normal electrostatic
attraction with the nicotinamide of NADP+ (Fig. 2B). Steric interac-
tions between the 29- and 30-methyl groups of oleanolic acid and
the Trp111 indole ring prevent the carboxylic group of oleanolic
acid from inserting into the anionic binding site of AKR1B1 to form
hydrogen bonds or electrostatic interactions with the co-factor. In0–oleanolic acid docking model. Flufenamic acid: green, oleanolic acid: deep teal,
le distance between ﬂufenamic acid C3 and Trp112 Cz2: dashed blue line, water: red
Fig. 3. Side chain orientation of Trp112 (Trp111) determines inhibitor selectivity between AKR1B10 and AKR1B1. Left: the AKR1B10 holoenzyme. Trp112 located at the B10-
position leaves a wide entrance to the anionic site to accommodate selective AKR1B10 inhibitors with bulky and rigid scaffolds (yellow triangle a). Right: ‘‘AKR1B1-like’’
AKR1B10 active site. Some AKR1B1 inhibitors (blue quadrangle b) that induce opening of the ‘‘speciﬁcity pocket’’ (grey) and cause Trp112 to ﬂip to the B1-position strongly
inhibit AKR1B10.
L. Zhang et al. / FEBS Letters 587 (2013) 3681–3686 3685contrast, in AKR1B10, the 29- and 30-methyl groups can
strengthen oleanolic acid binding by forming hydrophobic contacts
with Trp112. Thus, the binding mode not only coincides with the
generally observed phenomenon that a strong hydrogen bond
donating group is required for AKR1B10/AKR1B1 inhibitors to bind
at the anionic site, but also provides a straightforward explanation
for the high selectivity of oleanolic acid. Consistent with this
hypothesis, erythrodiol, a derivative of oleanolic acid with the car-
boxyl group substituted by a hydroxyl group, exhibits very poor
binding afﬁnity toward AKR1B10 [10]. It also becomes clear why
5b-cholanic acid and isolithocholic acid are both highly selective
AKR1B10 inhibitors, while 5b-cholanic acid methyl ester loses
most of its binding ability towards AKR1B10 and AKR1B1 [28]
(Table S5).
The binding modes of many other inhibitors listed in Table S1
are not known yet. However, the strong activities toward AKR1B10
and AKR1B1, but weak activity toward AKR1A1 of chromene-3-car-
boxamide derivatives [27], suggest that this type of compound
triggers the ‘‘speciﬁcity pocket’’ opening and Trp112 ﬂip to give
an ‘‘AKR1B1-like’’ active site in AKR1B10. Furthermore, the appar-
ent tendency of compounds such as c-mangostin [29], curcumin
[13], and 5a-pregnane-21-ol-3, 20-dione [28] to selectively inhibit
AKR1B10 indicates that the increased accessibility of the anionic
site of AKR1B10 is essential for their selectivity. To support this
mechanism, we prepared the AKR1B10 Gln114Thr/Ser304Cys
double mutant. These mutations are expected to loosen the
Gln114-centered hydrogen bond network and allow the Trp112
side-chain to ﬂip to the B1-position. As expected, ﬂufenamic acid
and oleanolic acid only inhibit this mutant very weakly, while
zopolrestat and epalrestat are strong inhibitors of this mutant
(Table 1).
4. Conclusion
As summarized in Table 1 and Fig. 3, the previously reported
binding site geometry similarity between AKR1B1–inhibitor and
AKR1B10–inhibitor complexes could be the result of inhibitor-in-
duced ‘‘speciﬁcity pocket’’ opening and Trp112 side-chain ﬂip at
the active site of AKR1B10. The native conformations of Trp112
(Trp111) affect the inhibitor selectivity between AKR1B10 and
AKR1B1. AKR1B1 inhibitors that are able to open the ‘‘speciﬁcity
pocket’’ of AKR1B1 can also do so with AKR1B10 and induce a
Trp112 side chain ﬂip, resulting an ‘‘AKR1B1-like’’ active site in
AKR1B10. Thus, these compounds are still good AKR1B10
inhibitors. AKR1B1 inhibitors that are not able to open the ‘‘speci-
ﬁcity pocket’’ of AKR1B1 could be either good AKR1B10 inhibitorsor not, depending on the ﬂexibility of their structure. The wider
entrance to the anionic site of AKR1B10 provided by the native
Trp112 side chain orientation explains why selective AKR1B10
inhibitors are apt to be bulky and rigid molecules. Whether similar
phenomena also occur in other AKRs–inhibitor interactions and
how the subtle structural differences affect the screening and
rational design of highly selective AKRs inhibitors are currently
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